Core Viewpoint - The company is committed to implementing the national innovation-driven development strategy by addressing key issues in its southwestern industrial cluster, including the decentralization of R&D platforms, insufficient attraction of high-end talent, and the need to enhance innovation capabilities [1] Group 1 - The company plans to establish a Southwestern R&D center in Chengdu [1] - The total investment for the project is estimated at 99.298 million yuan [1] - The construction period for the R&D center is projected to be 18 months [1]

格隆汇2月10日丨中钨高新(000657.SZ)公布，为满足中钨高新西南研发中心建设项目资金需求，董事会 同意公司与自贡市国有资本投资运营集团有限公司按原股比共同向自贡硬质合金有限责任公司（简称自 硬公司）增资9,000万元，增资完成后自硬公司注册资本将由87,276.53万元变为96,276.53万元。 ...

格隆汇2月10日丨彤程新材(603650.SH)公布，公司已于2026年2月6日向香港联合交易所有限公司 （称"香港联交所"）递交了发行境外股份（H股）并在香港联交所主板挂牌上市（称"本次发行并上 市"）的申请，并于2026年2月8日在香港联交所网站刊登了本次发行并上市的申请资料。 ...

Core Viewpoint - The company, HaiMuxing (688559.SH), reported a significant change in shareholding by its shareholder, Tai'an Haihe Henghui No. 2 Investment Partnership, which has reduced its stake in the company, impacting the overall shareholding structure [1] Summary by Relevant Sections - **Shareholder Activity** - Tai'an Haihe reduced its shareholding by 1,572,000 shares from 12,234,000 shares to 10,662,000 shares between December 23, 2025, and February 10, 2026 [1] - This reduction led to a decrease in the shareholding percentage from 27.55% to 26.92% [1]

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The ultra-long-acting antihypertensive drug LDR2402 targeting the AGT site has entered Phase II clinical trials, with the first subject already dosed [1] - The clinical trial application (IND) for the small nucleic acid new drug LDR2515 injection (targeting INHBE) for obesity treatment has recently received implied approval from the China National Medical Products Administration (CDE) [1] Group 2: Financing and Shareholding - XianYuan is a subsidiary and affiliated party of Chengdu XianDao, with a registered capital of 17.24 million yuan [1] - Chengdu XianDao plans to subscribe to an additional registered capital of 24 million yuan at a pre-investment valuation of 450 million yuan, increasing its shareholding in XianYuan from 23.20% [1] - The lead investor in this financing round is Chengdu Angel DaoYuan GuoSheng Medical Health Venture Capital Partnership (Limited Partnership), with other investors including affiliated parties Cao Jiaming and Huabo Medical [1]

格隆汇2月10日丨中钨高新(000657.SZ)公布，为进一步扩大PCB钻针棒市场占有率、保障公司PCB刀具 原料需求、巩固公司PCB刀具全产业链龙头地位，董事会同意株洲硬质合金集团有限公司（简称株硬公 司）以1.45亿元实施新增PCB钻针棒3,000万支/年项目，建设期12个月。 ...

Group 1 - The core point of the article is that Zhongtung High-tech (000657.SZ) has approved a capital increase of 100 million yuan to Zhuhai Hard Company to support the construction funding needs for a new annual production capacity of 30 million PCB drill needle rods [1] Group 2 - After the capital increase, Zhuhai Hard Company's registered capital will rise from 2,453.6113 million yuan to 2,553.6113 million yuan [1]

格隆汇2月10日丨东阿阿胶(000423.SZ)公布，公司拟以14.85亿元（其中固定资产投资14.21亿元，铺底 流动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食同源食品、保健品、功能性 食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。 ...

格隆汇2月10日｜南下资金今日净买入港股8465.67万港元。其中： 净买入美团-W 5.45亿、中国海洋石油4.2亿、中芯国际3.76亿、长飞光纤光缆2.87亿、小米集团-W 2.03亿、阅文集团1.63亿、阿里巴巴-W 1.6亿； 净卖出腾讯控股14.02亿、泡泡玛特2.34亿、招金矿业2.2亿。 据统计，南下资金已连续9日净买入小米，共计40.236亿港元；连续5日净买入阿里，共计45.9095亿港元；连续3日净买入中芯国际，共计9.7441亿港元。(格 隆汇) | 近60日南下净买入(亿) | | --- | | 名称 | 涨跌幅 | 净买入额(亿) | 成交额 | 名称 | | --- | --- | --- | --- | --- | | 腾讯控股 | -1.6% | -7.53 | 52.29亿 | 腾讯控股 | | 阿里巴巴-W | 1.7% | 4.31 | 26.52亿 | 阿里巴巴-W | | 长飞光纤光缆 | 8.9% | -1.21 | 20.61 亿 | 长飞光纤光缆 | | 美团-W | -2.5% | 3.63 | 19.74亿 | 中芯国际 | | 泡泡玛特 | 4.9% | ...

Group 1 - The company *ST Jinling (300091.SZ) announced a capital reserve transfer to increase share capital, with a reference price calculation formula for the ex-rights date [1] - The company has applied to the Shenzhen Stock Exchange for a one-day suspension of trading on February 11, 2026, which is the share registration date for the capital reserve transfer [1] - The company plans to resume trading on February 12, 2026, following the suspension [1]